Leader Heartburn Relief and Pexidartinib Hydrochloride
Determining the interaction of Leader Heartburn Relief and Pexidartinib Hydrochloride and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADJUST DOSING INTERVAL: Coadministration with acid-reducing agents may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption. Concomitant administration of esomeprazole, a proton pump inhibitor, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 50%, respectively. The effect of coadministration with an H2-receptor antagonist or locally-acting antacids on pexidartinib pharmacokinetics is unknown. MANAGEMENT: If acid-suppression therapy is required, pexidartinib should be administered at least 2 hours before or 10 hours after taking an H2-receptor antagonist or 2 hours before or 2 hours after taking a locally-acting antacid. Concomitant use of pexidartinib with proton pump inhibitors should be avoided. References "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Professional:ADJUST DOSING INTERVAL: Coadministration with acid-reducing agents may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption. Concomitant administration of esomeprazole, a proton pump inhibitor, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 50%, respectively. The effect of coadministration with an H2-receptor antagonist or locally-acting antacids on pexidartinib pharmacokinetics is unknown.
MANAGEMENT: If acid-suppression therapy is required, pexidartinib should be administered at least 2 hours before or 10 hours after taking an H2-receptor antagonist or 2 hours before or 2 hours after taking a locally-acting antacid. Concomitant use of pexidartinib with proton pump inhibitors should be avoided.
- "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Generic Name: cimetidine
Brand name: Tagamet HB, Tagamet
Synonyms: n.a.
Generic Name: pexidartinib
Brand name: Turalio
Synonyms: Pexidartinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Leader Heartburn Relief-Pfizerpen
- Leader Heartburn Relief-Pharaon Tea
- Leader Heartburn Relief-Pharmorubicin Pfs
- Leader Heartburn Relief-Phazyme
- Leader Heartburn Relief-Phazyme Liquid Gas Relief, Maximum Strength
- Leader Heartburn Relief-Phena-Plus
- Pexidartinib Hydrochloride-Leader Nicotine Polacrilex gum, lozenge
- Pexidartinib Hydrochloride-Leader Sleep Aid
- Pexidartinib Hydrochloride-Ledipasvir and sofosbuvir
- Pexidartinib Hydrochloride-Ledipasvir and Sofosbuvir Tablets
- Pexidartinib Hydrochloride-Leena
- Pexidartinib Hydrochloride-Lefamulin